HighTower Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

HighTower Advisors LLC lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 54.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,594 shares of the biopharmaceutical company’s stock after selling 19,580 shares during the quarter. HighTower Advisors LLC’s holdings in Halozyme Therapeutics were worth $793,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Raymond James Financial Inc. bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $21,838,000. Janney Montgomery Scott LLC lifted its holdings in Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after buying an additional 251,711 shares in the last quarter. Victory Capital Management Inc. boosted its position in Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock valued at $31,112,000 after buying an additional 243,940 shares during the period. Boston Trust Walden Corp grew its stake in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after acquiring an additional 191,465 shares in the last quarter. Finally, Hantz Financial Services Inc. purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $9,260,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO opened at $64.48 on Friday. The firm has a market capitalization of $7.97 billion, a PE ratio of 18.80, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The business’s 50-day moving average is $58.98 and its two-hundred day moving average is $54.85. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Benchmark reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.